KRBP - Kiromic BioPharma, Inc.
After hours:
| Previous close | 3.3400 |
| Open | 3.2700 |
| Bid | 3.0500 x 800 |
| Ask | 3.0700 x 1000 |
| Day's range | 2.9900 - 3.3765 |
| 52-week range | 2.5900 - 22.8000 |
| Volume | |
| Avg. volume | 355,577 |
| Market cap | 2.977M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -50.5700 |
| Earnings date | 10 Aug 2023 - 14 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireKiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
HOUSTON, May 01, 2023--Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
Business WireKiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
HOUSTON, April 03, 2023--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial to evaluate KB-GDT-01, or Deltacel, in combination with an
Business WireKiromic BioPharma Announces Reverse Stock Split
HOUSTON, March 10, 2023--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023. Kiromic common stock will begi
Business WireKiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
HOUSTON, February 28, 2023--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 (trademark: Deltacel™) administered alone and in combination with a non-biologic
Business WireTwo Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote "FOR" All Proxy Proposals
HOUSTON, February 23, 2023--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that Institutional Shareholder Services (ISS) and Glass Lewis & Co. (Glass Lewis), two leading independent proxy advisory firms, have issued recommendations that Kiromic stockholders vote FOR all
Business WireKiromic BioPharma CEO Issues Letter to Stockholders
HOUSTON, February 16, 2023--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, today issued the following letter to stockholders from its CEO Pietro Bersani.
Business WireKiromic BioPharma Arranges Up to $10 Million Financing
HOUSTON, October 27, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD, a partnership managed by Yorkville Advisors Global LP, a global investment manager, to sell up to $8 mi
Business WireKiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
HOUSTON, October 06, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it received validating written feedback on October 4, 2022 from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel™ development strategy.
Business WireKiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer
HOUSTON, July 12, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company’s Vice President of Research & Development and Clinic
Business WireKiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
HOUSTON, July 07, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the timely completion of construction on its expanded current good manufacturing practice (cGMP) manufacturing facility in Houston. This significant milestone was accomplished within the time
Business WireKiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
HOUSTON, June 21, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and data mining platform to discover and develop cell therapies with a focus on immuno-oncology, announces a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT™.